Novel Microdevices

About Novel Microdevices

Novel Microdevices, Inc. is pioneering the development of Novel Dx, an ultra-portable, point-of-care molecular diagnostics system. This innovative device is designed to detect sexually transmitted diseases, including antibiotic-resistant infections, using advanced Nucleic Acid Amplification Techniques (NAAT). Weighing only four pounds and battery-powered, Novel Dx provides lab-quality results in under 30 minutes, enabling patients to be tested, diagnosed, and treated in a single visit. The system is designed to be CLIA waived, making it accessible for use in various healthcare settings without the need for specialized laboratory personnel. The business primarily serves healthcare providers, clinics, and potentially remote or resource-limited settings where quick and accurate diagnostics are crucial. Novel Microdevices operates in the medical diagnostics market, focusing on rapid, accurate, and cost-effective solutions. The company generates revenue through the sale of its diagnostic devices and test-specific cartridges.